Association of Dental and Periodontal Status with Bisphosphonate-related Osteonecrosis of the Jaws. A Retrospective Case Controlled Study

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2014 Apr 5

PMID 24701224

Citations 15

Authors

Marcin Kos

Affiliations

Soon will be listed here.

Abstract

Introduction: To assess the association of oral hygiene, dental caries, and periodontal status with bisphosphonate-related osteonecrosis of the jaws.

Material And Methods: A retrospective case-control study on 81 patients treated for neoplasms with bone metastases. Twenty-nine patients with bone necrosis and 52 controls treated with bisphosphonates were compared using the Oral Hygiene Index, Decay, Missing, Filled Teeth, Community Periodontal Index of Treatment Needs, and Residual Periodontal Bone. The null hypothesis stated that there was no difference in parameters of oral health between patients with and without bone necrosis. Differences of means of above-mentioned variables were compared between the groups with Student's t-test or Mann-Whitney rank sum test and χ(2) test. Value of p ≤ 0.05 was considered significant.

Results: Poorer oral hygiene (OHIs 1.94 vs. 1.32; p = 0.065), more advanced dental caries (DMFT 26.85 vs. 22.87; p = 0.05), and more advanced periodontal disease (CPITN: = 0: 21.05% vs. 42.51%; = 1 13.16% vs. 7.29%; = 2: 0% vs. 15.38%; = 3: 65.79% vs. 28.34%; = 4: 0% vs. 6.48%, Residual periodontal bone 73.1% vs. 80.51%; p = 0,001) were characteristic of patients with bisphosphonate related jaw necrosis when compared with control group. An advanced dental caries or periodontal disease required surgical intervention which directly contributed to the development of the bone necrosis.

Conclusions: Dental and periodontal disease can lead to bisphosphonate-related osteonecrosis of the jaw. Oncologic patients treated with bisphosphonates should be offered preventive care to reduce dental plaque, calculus, dental caries, and periodontal disease.

Citing Articles

Impact of Bisphosphonate Therapy on Oral Health in Patients with Breast and Prostate Cancer and Bone Metastases: A Comprehensive Study.

Calik J, Calik K, Sauer N, Zdzislaw B, Giedziun P, Mackiewicz J Cancers (Basel). 2024; 16(6).

PMID: 38539459 PMC: 10969311. DOI: 10.3390/cancers16061124.

A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.

Sobczak-Jaskow H, Kochanska B, Drogoszewska B Medicina (Kaunas). 2023; 59(6).

PMID: 37374277 PMC: 10301423. DOI: 10.3390/medicina59061073.

Calabria E, Antonelli A, Barone S, Adamo D, Salviati M, Cerra M Dent J (Basel). 2023; 11(6).

PMID: 37366670 PMC: 10297522. DOI: 10.3390/dj11060147.

Potential Relationship between Poor Oral Hygiene and MRONJ: An Observational Retrospective Study.

DAgostino S, Valentini G, Dolci M, Ferrara E Int J Environ Res Public Health. 2023; 20(7).

PMID: 37048016 PMC: 10094150. DOI: 10.3390/ijerph20075402.

Composition and Properties of Saliva in Patients with Osteoporosis Taking Antiresorptive Drugs.

Sobczak-Jaskow H, Kochanska B, Drogoszewska B Int J Environ Res Public Health. 2023; 20(5).

PMID: 36901300 PMC: 10002130. DOI: 10.3390/ijerph20054294.

References

Kos M . WITHDRAWN: Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonisation. Med Hypotheses. 2011; 77(2):214-5. DOI: 10.1016/j.mehy.2011.04.015. View

Hornby S, Evans G, Hornby S, Pataki A, GLATT M, Green J . Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int. 2003; 72(4):519-27. DOI: 10.1007/s00223-002-2015-4. View

Hoff A, Toth B, Altundag K, Johnson M, Warneke C, Hu M . Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23(6):826-36. PMC: 2677083. DOI: 10.1359/jbmr.080205. View

Ganguli A, Steward C, Butler S, Philips G, Meikle S, Lloyd A . Bacterial adhesion to bisphosphonate coated hydroxyapatite. J Mater Sci Mater Med. 2005; 16(4):283-7. DOI: 10.1007/s10856-005-0625-x. View

Marx R, Sawatari Y, Fortin M, Broumand V . Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63(11):1567-75. DOI: 10.1016/j.joms.2005.07.010. View

Aghaloo T, Kang B, Sung E, Shoff M, Ronconi M, Gotcher J . Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res. 2011; 26(8):1871-82. PMC: 3596511. DOI: 10.1002/jbmr.379. View

Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G . Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2008; 20(1):137-45. DOI: 10.1093/annonc/mdn526. View

Dimopoulos M, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M . Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2008; 20(1):117-20. DOI: 10.1093/annonc/mdn554. View

Boonyapakorn T, Schirmer I, Reichart P, Sturm I, Massenkeil G . Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008; 44(9):857-69. DOI: 10.1016/j.oraloncology.2007.11.012. View

10.

Pampu A, Dolanmaz D, Tuz H, Karabacakoglu A . Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis. J Oral Maxillofac Surg. 2006; 64(8):1232-6. DOI: 10.1016/j.joms.2006.04.038. View

11.

Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K . Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab. 2009; 28(2):165-75. DOI: 10.1007/s00774-009-0128-9. View

12.

Bamias A, Kastritis E, Bamia C, Moulopoulos L, Melakopoulos I, Bozas G . Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23(34):8580-7. DOI: 10.1200/JCO.2005.02.8670. View

13.

Wu S, Dahut W, Gulley J . The use of bisphosphonates in cancer patients. Acta Oncol. 2007; 46(5):581-91. DOI: 10.1080/02841860701233435. View

14.

Tarassoff P, Csermak K . Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg. 2003; 61(10):1238-9. DOI: 10.1016/j.joms.2003.09.001. View

15.

Jee J, Lee W, Lee B . The influence of alendronate on the healing of extraction sockets of ovariectomized rats assessed by in vivo micro-computed tomography. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110(2):e47-53. DOI: 10.1016/j.tripleo.2010.03.025. View

16.

Terezakis E, Needleman I, Kumar N, Moles D, Agudo E . The impact of hospitalization on oral health: a systematic review. J Clin Periodontol. 2011; 38(7):628-36. DOI: 10.1111/j.1600-051X.2011.01727.x. View

17.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

18.

Kos M, Kuebler J, Luczak K, Engelke W . Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg. 2009; 38(4):255-9. DOI: 10.1016/j.jcms.2009.06.005. View

19.

Mirzai R, Chang C, Greenspan A, Gershwin M . The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma. 1999; 36(1):77-95. DOI: 10.3109/02770909909065152. View

20.

Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D . Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006; 134(6):620-3. DOI: 10.1111/j.1365-2141.2006.06230.x. View